19:09 , Aug 7, 2018 |  BC Extra  |  Company News

Management tracks: GSK, J&J, Denali

GlaxoSmithKline plc (NYSE:GSK; LSE:GSK) hired Iain Mackay as CFO and executive director. Mackay, who is group finance director at HSBC, will join GSK on Jan. 14, 2019 as CFO designate and take formal accountability as...
19:57 , Jul 13, 2018 |  BC Week In Review  |  Company News

Adlai Nortye gets rights to buparlisib from Novartis

Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) gained exclusive, worldwide rights to cancer candidate buparlisib (BKM120) from Novartis AG (NYSE:NVS; SIX:NOVN). Financial terms were not disclosed. Adlai Nortye has global rights to develop and commercialize...
19:47 , Jul 10, 2018 |  BC Extra  |  Company News

Adlai Nortye gets rights to Novartis' buparlisib

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) gained exclusive, worldwide rights to cancer candidate buparlisib (BKM120) from Novartis AG (NYSE:NVS; SIX:NOVN). Financial terms were not disclosed. Adlai Nortye has global rights to...
18:09 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Adlai Nortye raises $50M series B

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital. Matrix Partners China, DT Capital Partners and Yahui Precision Medicine Fund also...
20:49 , Jun 26, 2018 |  BC Extra  |  Financial News

Adlai Nortye raises $50M in series B

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital. Matrix Partners China, DT Capital Partners and Yahui Precision Medicine Fund also...
16:24 , Jan 26, 2018 |  BC Week In Review  |  Company News

Adlai Nortye receives rights to solid tumor candidate E7046 from Eisai

Eisai Co. Ltd. (Tokyo:4523) granted Adlai Nortye Co. Ltd. (NEEQ:870946) exclusive, worldwide rights outside of parts of Asia to develop and commercialize solid tumor candidate E7046. Specifically, the deal excludes Japan, Korea, Taiwan, Thailand, India,...
20:36 , Nov 17, 2017 |  BC Week In Review  |  Company News

Oncolytics grants Adlai Nortye Asian rights to Reolysin

Oncolytics Biotech Inc. (TSX:ONC; OTCQX:ONCYF) granted Adlai Nortye (NEEQ:870946) exclusive rights to develop and commercialize Reolysin pelareorep in China, including Hong Kong and Macau, Singapore, South Korea and Taiwan. Oncolytics will receive $5.3 million up...